Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava in Taiwan
Details : Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug res...
Brand Name : Xerava
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 11, 2022
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
